| Jack D Hornby, MD | |
|
418 Windward Way, Kalispell, MT 59901-2680 | |
| (406) 752-6100 | |
| (406) 755-3720 |
| Full Name | Jack D Hornby |
|---|---|
| Gender | Male |
| Speciality | Psychiatry & Neurology - Psychiatry |
| Location | 418 Windward Way, Kalispell, Montana |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1306935184 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084P0800X | Psychiatry & Neurology - Psychiatry | 6089 (Montana) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Jack D Hornby, MD T-9 Fort Missoula, Missoula, MT 59804-7202 Ph: (406) 532-8400 | Jack D Hornby, MD 418 Windward Way, Kalispell, MT 59901-2680 Ph: (406) 752-6100 |
News Archive
Janssen-Cilag International NV today announced the early stopping of PCYC-1112-CA, the Phase 3 study of ibrutinib in the treatment of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, based on the recommendation of an Independent Data Monitoring Committee, which concluded that the study showed a significant difference in progression-free survival as compared to the control, the primary endpoint of the study.
A drug approved to treat certain types of cancer has shown promising results in the treatment of patients with scleroderma, according to results from an open-label Phase II trial. While the drug's efficacy must be demonstrated in a Phase III trial, the gold standard for testing a drug, researchers are optimistic that Gleevec- (imatinib) could potentially be a weapon against the chronic connective tissue disease for which a treatment has remained elusive.
Palbociclib, an investigational oral medication that works by blocking molecules responsible for cancer cell growth, is well tolerated and extends progression-free survival (PFS) in newly diagnosed, advanced breast cancer patients, including those whose disease has stopped responding to traditional endocrine treatments.
ThromboGenics NV, a biopharmaceutical company focused on developing innovative ophthalmic medicines, announces today that it has entered into an agreement with Alcon (a division of Novartis), the global leader in eyecare, for the commercialization of ocriplasmin in all markets outside the U.S.
› Verified 7 days ago
Joseph Hugh Boyle, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 75 Claremont St, Suite C, Kalispell, MT 59901 Phone: 406-758-5155 | |
Robert D Schimpff, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 202 Conway Dr, Suite 100, Kalispell, MT 59901 Phone: 406-751-5666 Fax: 406-755-0971 | |
Kurt D Lindsay, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 200 Commons Way Ste C, Kalispell, MT 59901 Phone: 406-752-5095 Fax: 406-752-5058 | |
Constance Mash, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 200 Heritage Way, Kalispell, MT 59901 Phone: 406-756-3950 Fax: 406-756-3957 | |
Tanner Ferderer, Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 200 Commons Way Ste C, Kalispell, MT 59901 Phone: 406-752-5095 Fax: 406-751-3079 | |
Victor C. Houser Iii, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 355 1st Avenue West N, Kalispell, MT 59901 Phone: 406-755-6200 Fax: 406-755-6208 | |
Melanie A. Klawiter, Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 200 Commons Way Ste C, Kalispell, MT 59901 Phone: 406-752-5095 |